Autorizzazione allo studio clinico sperimentale, farmacologico, profit, denominato: “A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY-STAGE PARKINSON’S DISEASE”. NUMERO DI PROTOCOLLO: BN44715
Deliberazione - 62 - 05/02/2026
Deliberazione
N° 62
del 05/02/2026








